Cost-effectiveness of sirolimus-eluting stents in percutaneous coronary interventions in Brazil.
OBJECTIVE
To compare the cost-effectiveness ratios of sirolimus-eluting stents (SES) with bare-metal stents (BMS) under two perspectives: the "supplementary medical system" (health plans and private patients) and the public health (SUS) system.


METHODS
A decision-analytic model using three different therapeutic strategies for coronary lesions: percutaneous coronary intervention (PCI) with BMS; with SES; or with BMS followed by SES to treat symptomatic restenosis. Study endpoints were one-year event-free survival and life expectancy. Decision trees were constructed using the results of published registries and clinical trials.


RESULTS
One-year restenosis-free survival was 92.7% with SES and 78.8% with BMS. Estimated life expectancy was very similar for all the strategies, ranging from 18.5 to 19 years. Under a nonpublic perspective, the cost difference in the first year between BMS and SES was R$3,816, with an incremental cost-effectiveness ratio of R$27,403 per event avoided in one year. Under the SUS perspective, the cost per event avoided in one year was R$47,529. In the sensitivity analysis, probability of restenosis, risk reduction expected with SES, the price of the stent and cost of treating restenosis were all important predictors. In the Monte Carlo simulation, data per years of life saved showed very high cost-effectiveness ratios.


CONCLUSIONS
In the Brazilian model, the cost-effectiveness ratios for SES were elevated. The use of SES was more favorable for patients with high risk of restenosis, as it is associated with elevated costs in restenosis management of and under a nonpublic perspective.
Polanczyk
Carisi Anne
CA
Hospital de Clínicas de Porto Alegre, Programa de Pós-graduação em Cardiologia da UFRGS, Porto Alegre, RS, Brazil. carisi@terra.com.br
Wainstein
Marco V
MV
Ribeiro
Jorge Pinto
JP
D015906:Angioplasty, Balloon, Coronary / Q000191:economics*; D001938:Brazil; D003327:Coronary Disease / Q000191:economics / Q000628:therapy*; D023903:Coronary Restenosis / Q000517:prevention & control; D003362:Cost-Benefit Analysis; D018572:Disease-Free Survival; D054855:Drug-Eluting Stents / Q000191:economics; D017048:Health Care Costs / Q000706:statistics & numerical data*; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D020123:Sirolimus / Q000008:administration & dosage*; D015607:Stents / Q000191:economics*; D016896:Treatment Outcome
D007166:Immunosuppressive Agents; D020123:Sirolimus